The Institute for Clinical and Economic Review (ICER) on Tuesday announced plans to develop a review assessing the comparative clinical effectiveness and value of biologic therapies for moderate-to-severe asthma.
The report is set to be reviewed during a November public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), one of ICER’s three independent evidence appraisal committees.
ICER’s report is expected to include five therapies: dupilumab (Dupixent, Sanofi/Regeneron), omalizumab (Xolair, Genentech/Novartis), mepolizumab (Nucala, GlaxoSmithKline), reslizumab (Cinqair, Teva), and benralizumab (Fasenra, AstraZeneca).
ICER previously reviewed mepolizumab for its use in severe eosinophilic asthma and dupilumab for its use in atopic dermatitis. Dupilumab is currently under FDA review for use as add-on maintenance treatment in moderate-to-severe asthma, with an approval decision expected in October this year.
An open input period began Tuesday and is intended to allow stakeholders to share key information relevant to the development of the evidence reports. Comments will be accepted from all interested stakeholders on either topic until 5 p.m. EST May 10. During this time, ICER will also contact key patient groups and clinical experts to gain further insights on the patient perspective and clinical context of treatment for these conditions.
